✦ LIBER ✦

Phase II trial of isoflavone in prostate-specific antigen recurrent prostate cancer after previous local therapy

✍ Scribed by John M Pendleton; Winston W Tan; Satoshi Anai; Myron Chang; Wei Hou; Kathleen T Shiverick; Charles J Rosser

Book ID: 115011252
Publisher: BioMed Central
Year: 2008
Tongue: English
Weight: 270 KB
Volume: 8
Category: Article
ISSN: 1471-2407
DOI: 10.1186/1471-2407-8-132

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Hormonal therapy options for prostate-sp

Hormonal therapy options for prostate-specific antigen-only recurrence of prostate cancer after previous local therapy

✍ Judd W. Moul; Alexandre R. Zlotta 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 87 KB

Definition and management of prostate-sp

Definition and management of prostate-specific antigen recurrence after local therapy

✍ Luis Martínez-Piñeiro; Carlos Sánchez; Felipe Cáceres 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 81 KB

Predictors of mortality after androgen-d

Predictors of mortality after androgen-deprivation therapy in patients with rapidly rising prostate-specific antigen levels after local therapy for prostate cancer

✍ Neesha A. Rodrigues; Ming-Hui Chen; William J. Catalona; Kimberly A. Roehl; Jero 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 156 KB 👁 2 views

Prostate-specific antigen recurrence and

Prostate-specific antigen recurrence and mortality after conventional dose radiation therapy in select men with low-risk prostate cancer

✍ Joshua H. Petit; Ming-Hui Chen; Marian Loffredo; Brenda Sussman; Andrew A. Rensh 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 155 KB 👁 1 views

Tumour length of the largest focus predi

Tumour length of the largest focus predicts prostate-specific antigen-based recurrence after radical prostatectomy in clinically localized prostate cancer

✍ Ryuichi Mizuno; Jun Nakashima; Makio Mukai; Hajime Okita; Michio Kosugi; Eiji Ki 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 188 KB

Phase II Trial of Sunitinib for the Ther

Phase II Trial of Sunitinib for the Therapy of Progressive Metastatic Castration-Refractory Prostate Cancer After Previous Docetaxel Chemotherapy

✍ Guru Sonpavde; Thomas E. Hutson; William R. Berry; Kristi A. Boehm; Lina Asmar 📂 Article 📅 2008 🏛 CIG Media Group, LP. 🌐 English ⚖ 93 KB